We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




HDL Subclasses Linked to Mortality in Heart Failure Patients

By LabMedica International staff writers
Posted on 11 Feb 2019
Print article
Image: The Olympus AU680 automated analyzer (Photo courtesy of Beckman Coulter).
Image: The Olympus AU680 automated analyzer (Photo courtesy of Beckman Coulter).
Heart failure (HF) is a frequent cause of morbidity and mortality worldwide and is defined by the as an abnormality of the cardiac structure and function, resulting in a diminished ability of the heart to maintain optimal perfusion of metabolizing tissues.

The link between high-density lipoproteins (HDL) subclasses and the prognosis of cardiovascular diseases remains controversial. It is important to note that HDL particles comprise two major subclasses, namely large buoyant HDL2 particles and smaller, denser HDL3 particles. Accordingly, quantity of the total HDL-C is dominated by the contribution of the larger, cholesterol-rich HDL2.

Scientists at University of Zagreb School of Medicine (Zagreb, Croatia) and their colleagues evaluated the prognostic value of the HDL subclasses 3 and 2 cholesterol (HDL3-C, HDL2-C) as well as of total HDL-C for 3-month mortality in acute heart failure (AHF) patients. Serum samples of 132 patients [65 (49.2%) were female and median and range for age were 77.3 (45.5–92.4) years], were available for the analyses. Of these, 35 (26.5%) died within three months of onset of AHF.

The collection of the blood samples, the standard laboratory methods and measurements of small, large and total HDL-particles (HDL-P) have been described in previous reports on this AHF cohort. The levels of total HDL cholesterol (HDL-C) and HDL3-C were measured using detergent-based homogeneous assays from Denka Seiken Co., Ltd. on an Olympus AU680 automated analyzer. HDL2-C was estimated by subtracting HDL3-C from total HDL-C.

The team reported that the median and range for serum levels of HDL3-C, HDL2-C, and total HDL-C were 0.49 (0.23–0.85) mmol/L, 0.62 (0.19–1.67) mmol/L and 1.13 (0.42–2.46) mmol/L, respectively. Univariate logistic regression analyses revealed a significant inverse association of HDL3-C (odds ratio (OR) 0.46 per 1-SD increase, 95% confidence interval (CI) 0.27–0.72,) with 3-month mortality, whereas concentrations of total HDL-C and HDL2-C showed no significant association. After adjustment for various laboratory and clinical parameters known to be associated with mortality in heart failure patients, HDL3-C concentrations remained significantly associated with 3-month mortality (OR 0.34 per 1-SD increase, 95% CI 0.15–0.74).

The authors concluded that low admission serum levels of HDL3-C are associated with increased 3-month mortality in AHF patients, whereas total HDL-C and HDL2-C showed no association. HDL3-C might thus be useful as a prognostic parameter in AHF. The study was published in the March 2019 issue if the journal Clinica Chimica Acta.

Related Links:
University of Zagreb School of Medicine

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.